The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer: Longer-term efficacy, safety, and quality-of-life results from the phase 3 KEYNOTE-590 study.
 
Jean-Philippe Metges
Honoraria - BMS; Lilly; Novartis; Sanofi; SynCoreBio
Travel, Accommodations, Expenses - Amgen; Amgen; LEO Pharma; MSD Oncology; MSD Oncology; MSD Oncology
 
Ken Kato
Honoraria - BMS; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - Bayer; BeiGene; MSD; Oncolys BioPharma; Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Chugai Pharma (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
 
Jong-Mu Sun
No Relationships to Disclose
 
Manish A. Shah
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst); Oncolys BioPharma (Inst)
 
Peter C. Enzinger
Consulting or Advisory Role - Arcus Biosciences; Astellas Pharma; AstraZeneca; Blueprint Medicines; Bristol-Myers Squibb/Celgene; Celgene; Coherus Biosciences; Daiichi Sankyo; Five Prime Therapeutics; IDEAYA Biosciences; Istari; Legend Biotech; Lilly; loxo; Merck; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Takeda; Turning Point Therapeutics; Xencor; Zymeworks
 
Antoine Adenis
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Merck Serono
Research Funding - Bayer (Inst); BeiGene (Inst); Roche (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck
 
Toshihiko Doi
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Oncolys BioPharma; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Abbvie; Amgen; Boehringer Ingelheim; Daiichi Sankyo; Janssen; Kyowa Hakko Kirin; MSD; Otsuka; Rakuten Medical; Sumitomo Dainippon; Takeda
Research Funding - Abbvie (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); IQvia (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst)
 
Takashi Kojima
Honoraria - Oncolys BioPharma; Ono Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; BMS; Merck; MSD
Research Funding - Astellas Amgen BioPharama (Inst); BMS (Inst); Chugai Pharma (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Parexel (Inst); Shionogi (Inst)
 
Zhigang Li
Research Funding - MSD (Inst)
 
Sung-Bae Kim
Honoraria - DAEHWA Pharmaceutical; ISU ABXIS
Consulting or Advisory Role - AstraZeneca; DAEHWA Pharmaceutical; ISU Abxis; Lilly (Inst)
Research Funding - Dongkook Pharma (Inst); Genzyme (Inst); Novartis (Inst)
 
Byoung Chul Cho
Leadership - Gencurix; Interpark Bio
Stock and Other Ownership Interests - Bridgebio; Cyrus therapeutics; Gencurix; Interpark Bio; Kanaph Therapeutics; Theravance
Consulting or Advisory Role - AstraZeneca; Blueprint medicines; Boehringer Ingelheim; Bridgebio; Bristol-Myers Squibb; Cyrus therapeutics; Guardant Health; Janssen; Joseah Biopharma; Kanaph Therapeutics; Lilly; Medpacto; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche; Takeda; Yuhan
Research Funding - Abbvie; AstraZeneca; Bayer; Blueprint medicines; Champions Oncology; Dizal Pharma; Dong-A ST; GI Innovation; Interpark Bio; Janssen; Lilly; Medpacto; Mogam Biotechnology Research Institue; MSD; Novartis; Ono Pharmaceutical; Yuhan
Patents, Royalties, Other Intellectual Property - Champions Oncology
Other Relationship - DAAN Biotherapeutics
 
Wasat Mansoor
Honoraria - BMS; BMS; Servier
Consulting or Advisory Role - BMS; SERVIER
Speakers' Bureau - Lilly
Travel, Accommodations, Expenses - Ipsen; SERVIER; SERVIER
 
Shau-Hsuan Li
Research Funding - MSD (Inst)
 
Patrapim Sunpaweravong
Honoraria - AstraZeneca; Baxter; Bristol-Myers Squibb; Eisai; Novartis; Roche
Consulting or Advisory Role - Amgen; Baxter; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi; Taiho Pharmaceutical
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; MSD; Novartis; Pfizer; Roche; Taiho Pharmaceutical
Research Funding - Novartis; Roche
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; MSD; Novartis; Pfizer; Roche; Taiho Pharmaceutical
 
MARIA ALSINA
Honoraria - Amgen; Bristol-Myers Squibb; SERVIER
Consulting or Advisory Role - Bristol-Myers Squibb; Lilly; MSD; SERVIER
Research Funding - MSD (Inst)
 
Gary L Buchschacher
Research Funding - AstraZeneca (Inst); Merck (Inst); Roche/Genentech (Inst)
 
Jimin Wu
Employment - Merck Sharp & Dohme
 
Sukrut Shah
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck
 
Pooja Bhagia
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Lin Shen
No Relationships to Disclose